From Genes to Innovative Oncology

from GENES to INNOVATIVE ONCOLOGY
Science
If we want to
solve problem / be successful
we need to:
a) work hard and wise
b) be lucky
Luck!!!
Poland
~38 mln country with high level of
genetic homogeneity
Górski B. et al. AJHG, June 2000
BRCA1 FOUNDER MUTATIONS
IN POLAND
GÓRSKI B. ET AL.
- PATENT NO P335917
- MULTIPLEX PCR - 50€
BRCA1 – REGISTRY –
SZCZECIN – POLAND
~ 5000 CARRIERS
THE LARGEST REGISTRY IN
THE WORLD
Poland – limited number of founder / recurrent mutations
in other cancer susceptibility genes
NBS1, NOD2, CHEK2, MSH2,
MLH1, APC
PENETRANCE
AND PROPORTION OF CANCERS
90%
80%
PENETRANCE
70%
60%
50%
40%
30%
20%
10%
0%
0%
20%
40%
60%
PROPORTION
80%
100%
HYPOTHESIS
> 90%
OF CANCERS
HAVE GENETIC CONSTITUTIONAL
BACKGROUND
Genetic contribution to all cancers: the
first demonstration
using the model of breast cancers from
Poland stratified
by age at diagnosis
and tumour pathology
Lubiński J. et al. Breast Can Res Treat 15 April 2008
Conclusion
At present, the major significance of the current findings is
the proof of principle
that there is no cancer without a genetic component.
DNA analysis will be the initial starting point
for prevention, surveillance and treatment schemes for all
adults.
TREATMENT
PROTOCOLS
Breast cancers with BRCA1 Treatment –
Neo-Adjuvant therapy
 Cis-platinum
 Complete remission
70% (n=50) breast cancer patients!!!
CHEMOTHERAPY
 Known drugs but selected
for sub-groups of patients !!!
 New drugs created against
constitutional changes !!!
Business
READ-GENE SA
 Rok założenia: 2005
 Giełda NewConnect
II 2009
V 2010
2,7 PLN 10,9 PLN
VII 2010
8,9 PLN
READ-GENE SA
 Baza intelektualna:
 zespół naukowców Ośrodka
Nowotworów Dziedzicznych PAM
 wyniki:
a) badań zespołu w PAM
(komercjalizacja w świecie)
b) badań własnych
READ-GENE SA
Baza laboratoryjna:
Ośrodek badawczo-rozwojowy (X 2010)
Misja
od GENÓW do
INNOWACYJNEJ ONKOLOGII
DIAGNOSTYKA
LECZENIE
(protokoły, leki)
PREWENCJA
(chemoprewencja)
ADVANTAGES
Cancer bio-bank probably the largest in the world
with biological samples and clinical data from >
180 000 cancer patients, relatives and controls.
Exclusive access basing on agreement with its
owner – IHCC, PMU, Szczecin Poland
ADVANTAGES
Exclusive license for international
commercialization of scientific data,
know–how and inventions of IHCC,
PMU. The huge potential to elaborate further
international inventions/patents
(by average 3 per year).
ADVANTAGES
Very unique system for scientific progress
at IHCC on elaboration of new: diagnostic genetic tests,
supplements for cancer prevention, treatment protocols,
drugs
A. Homogenous Polish population
– very low cost of genetic studies
B. Infrastructure of IHCC
READ-GENE SA
Projekt:
Dieta Antyrakowa
Read-Gene
DIETA ANTYRAKOWA READ-GENE
Stężenie Se, genotyp i ryzyko raka
u nosicielek mutacji BRCA1 (n=300)
Genotyp
Stężenie
Se
p
OR
CI
X1 n TT
60-80
0,0008 0,36
0,2-0,6
X1 TT
> 80
0,062
1,1-15,8
4,1
DIETA ANTYRAKOWA READ-GENE
- BRCA1: ok. 100 tys. Polek;
15 mln kobiet na świecie;
- dieta powinna być indywidualizowana
co do ilości selenu >>
www.dietaantyrakowa.com.pl
DIETA ANTYRAKOWA READ-GENE
- dystrybucja przez Read-Gene SA
artykułów spożywczych o ilości
selenu zbadanej w laboratorium
firmy;
FAR-REACHING
MAIN GOAL
 Global leadership in cancer
chemoprevention:
- modified food
- supplements
PLANS FOR 2010
 Intensification of own studies aimed to

introduction of Read-Gene products (unique
supplements) on the market
Construction of R&D Read-Gene centre with
laboratories (diagnostic, research),
outpatients and chemotherapy clinics –
Nov 2009 – Oct 2010
 [email protected]
 www.read-gene.com